Motus GI (NASDAQ:MOTS – Get Free Report) and West Pharmaceutical Services (NYSE:WST – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.
Insider & Institutional Ownership
20.1% of Motus GI shares are held by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are held by institutional investors. 0.3% of Motus GI shares are held by company insiders. Comparatively, 0.5% of West Pharmaceutical Services shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Motus GI and West Pharmaceutical Services, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Motus GI | 0 | 0 | 0 | 0 | N/A |
| West Pharmaceutical Services | 0 | 1 | 3 | 0 | 2.75 |
Valuation and Earnings
This table compares Motus GI and West Pharmaceutical Services”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Motus GI | $319,000.00 | 0.03 | -$12.87 million | ($15.64) | 0.00 |
| West Pharmaceutical Services | $2.95 billion | 8.13 | $593.40 million | $7.03 | 47.03 |
West Pharmaceutical Services has higher revenue and earnings than Motus GI. Motus GI is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Motus GI has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500.
Profitability
This table compares Motus GI and West Pharmaceutical Services’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Motus GI | -3,239.75% | -1,731.08% | -115.99% |
| West Pharmaceutical Services | 18.25% | 19.17% | 14.38% |
Summary
West Pharmaceutical Services beats Motus GI on 12 of the 13 factors compared between the two stocks.
About Motus GI
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.
